Patient preference for oral or intravenous chemotherapy: A randomised cross-over trial comparing capecitabine and Nordic fluorouracil/leucovorin in patients with colorectal cancer

European Journal of Cancer

Volumn 42, Issue 16, 2006, Pages 2738-2743

  Pfeiffer, P ^a   Mortensen, J P ^b   Bjerregaard, B ^c   Eckhoff, L ^a   Schonnemann K ^a   Sandberg, E ^d   Aabo, K ^e   Jakobsen, A ^b  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b LILLEBAELT HOSPITAL   (Denmark)

^c Sønderborg Hospital   (Denmark)

^d Esbjerg University Hospital   (Denmark)

^e VIBORG HOSPITAL   (Denmark)

Author keywords

5 FU LV; Capecitabine; Colorectal cancer; Patient preference

Indexed keywords

CAPECITABINE; FLUOROURACIL; FOLINIC ACID;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; COLORECTAL CARCINOMA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HAND FOOT SYNDROME; HOME CARE; HOSPITAL CARE; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; CROSS-OVER STUDIES; DEOXYCYTIDINE; FLUOROURACIL; HUMANS; INFUSIONS, INTRAVENOUS; LEUCOVORIN; MIDDLE AGED; PATIENT SATISFACTION;

EID: 33750179595     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2006.06.027     Document Type: Article

References (19)

1. Ragnhammar P., Hafström L., Nygren P., and Glimelius B. A Systematic overview of chemotherapy effects in colorectal cancer. Acta Oncologica 40 (2001) 282-308
2. Meyerhardt J.A., and Mayer R.J. Therapy for colorectal cancer. N Engl J Med 352 (2005) 476-487
3. Glimelius B., Jacobsen A., Graf W., et al. Bolus injection (2-4 minutes) versus short-term (10-20 minutes) infusion of 5-fluorouracil in patients with advanced colorectal cancer: A prospective randomised trial. Eur J Cancer 34 (1998) 674-678
4. Carlsson G., Graf W., Gustavsson B.G., et al. Sequential 5-fluorouracil and leucovorin in patients with advanced symptomatic gastrointestinal cancer. Eur J Cancer 26 (1990) 874-876
5. Nordic Gastrointestinal Tumor Adjuvant Therapy Group. Biochemical modulation of 5-fluorouracil: A randomised comparison of sequential methotrexate, 5-fluorouracil and leucovorin versus sequential 5-fluarouracil and leucovorin in patients with advanced symptomatic colorectal cancer. Ann Oncol 1993, 4, 235-241.
6. Jacobsen A., Berglund Å., Glimelius B., et al. Dose-effect relationship of bolus 5-fluorouracil in the treatment of advanced colorectal cancer. Acta Oncol 41 (2002) 525-531
7. Miwa M., Ura M., Nishida M., et al. Design of novel oral fluoropyrimidine carbamate, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J cancer 34 (1998) 1274-1281
8. Carmichael J., Popiela T., Radstone D., et al. Randomised comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 20 (2002) 3617-3627
9. Douillard J., Hoff P., Skillings J., et al. Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 20 (2002) 3605-3616
10. Wolmark N, Lembersky B, Colangelo L, et al. A phase III trial comparing oral UFT to FULV in stage II and III carcinoma of the colon: results of NSABP Protocol C-06. Proceedings ASCO 2004, Abstract #3508.
11. Van Cutsem E., Hoff P.M., Harper P., et al. Oral capecitabine vs intravenous 5-fluorouracil and leucovorin; integrated efficacy data and novel analyses from two large, a randomised, phase III trials. British J Cancer 90 (2004) 1190-1197
12. Twelves C., Wong A., Nowacki M.P., et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 352 (2005) 2696-2704
13. Liu G., Franssen E., Fitch M.I., et al. Patient preference for oral versus intravenous palliative chemotherapy. J Clin Oncol 15 (1997) 110-115
14. Borner M., Schöffski P., de Wit R., et al. Patient preferences and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. Eur J Cancer 38 (2002) 349-358
15. Glimelius B., Dahl O., Cedermark B., et al. Adjuvant chemotherapy in colorectal cancer: A joint analysis of randomised trials by the Nordic Gastrointestinal Tumour Adjuvant Therapy Group. Acta Oncologica 44 (2005) 904-912
16. de Gramont A., Bosset J.F., Milan C., et al. J Clin Oncol 15 (1997) 808-815
17. Saltz L.B. Another study of how to give fluorouracil?. J Clin Oncol 21 (2003) 3711-3712
18. Twelves C., Gollins S., Grieve R., and Samuel L. A randomised cross-over trial comparing patient preference for oral capecitabine and 5-fluorouracil/leucovorin regimens in patients with advanced colorectal cancer. Ann Oncol 17 (2006) 239-245
19. Rocha Lima A.P., and Del Giglio A. Randomised crossover trial of intravenous 5-FU versus UFT both modulated by leucovorin: a one-centre experience. Eur J Cancer Care 14 (2005) 151-154